Robert Arch, OncoSec Medical CEO
April 4, 2023 07:08 AM EDT
R&D

On­coSec re­ports flop for IL-12/Keytru­da com­bo in what may be fi­nal blow

Amber Tong

A six-year tri­al test­ing the com­bi­na­tion of On­coSec Med­ical’s IL-12 ther­a­py with Mer­ck’s Keytru­da has end­ed in fail­ure.

The com­bo

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times